Cargando…

ODP606 Long-term Efficacy of Setmelanotide in Patients With Bardet-Biedl Syndrome

OBJECTIVE: Bardet-Biedl syndrome (BBS) is a rare genetic disease characterized by hyperphagia (pathologic insatiable hunger) and early-onset, severe obesity believed to be driven by impaired signaling in the melanocortin-4 receptor (MC4R) pathway. In a Phase 2 and a pivotal Phase 3 trial, treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argente, Jesús, Beales, Philip, Clément, Karine, Dollfus, Hélène, Forsythe, Elizabeth, Haqq, Andrea, Haws, Robert, Martos-Moreno, Gabriel, Mittleman, Robert, Yanovski, Jack, Yuan, Guojun, Chung, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Adipose Tissue, Appetite, & Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624643/ http://dx.doi.org/10.1210/jendso/bvac150.029

Ejemplares similares

A Phase 3 Trial in Participants With Obesity Due to Bardet-Biedl Syndrome or Alström Syndrome: Efficacy and Safety of the Melanocortin 4 Receptor Agonist Setmelanotide
por: Haws, Robert, et al.
Publicado: (2021)

ODP605 Body Mass Index and Weight Reductions in Patients With SRC1 Genetic Variant Obesity After 1 Year of Setmelanotide
por: Martos-Moreno, Gabriel Á, et al.
Publicado: (2022)

ODP607 Long-term Efficacy of Setmelanotide in Patients With POMC or LEPR Deficiency Obesity
por: Clément, Karine, et al.
Publicado: (2022)

OR10-1 Body Mass Index and Weight Reductions in Patients With Obesity Due to Heterozygous Variants in POMC, PCSK1, and LEPR After 1 Year of Setmelanotide
por: Farooqi, Sadaf, et al.
Publicado: (2022)

Quality of life improvements following one year of setmelanotide in children and adult patients with Bardet–Biedl syndrome: phase 3 trial results
por: Forsythe, Elizabeth, et al.
Publicado: (2023)

RF24 | PSUN96 Setmelanotide in Patients With Heterozygous POMC, LEPR, SRC1, or SH2B1 Obesity: Design of EMANATE – A Placebo-Controlled Phase 3 Trial
por: Wabitsch, Martin, et al.
Publicado: (2022)

FRI082 Impact Of Setmelanotide On Metabolic Parameters And Vital Signs In Patients With Hypothalamic Obesity
por: Jennifer Abuzzahab, M, et al.
Publicado: (2023)

SAT656 Weight Reduction After 6 Months Of Setmelanotide Treatment In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Timing of Onset of Adverse Events With Setmelanotide, an MC4R Agonist, in Patients With Severe Obesity Due to LEPR or POMC Deficiency
por: Clément, Karine, et al.
Publicado: (2021)

RF24 | PSUN91 Body Mass Index and Weight Reduction in Patients With SH2B1 Genetic Variant Obesity After One Year of Setmelanotide
por: Argente, Jesús, et al.
Publicado: (2022)

FRI066 Treatment History And Comorbidities Reported By Patients With Hypothalamic Obesity Treated With Setmelanotide In A Phase 2 Trial
por: Roth, Christian L, et al.
Publicado: (2023)

FRI065 Trial Design Of A Double-blind, Randomized, Placebo-controlled, Phase 3 Study Of Setmelanotide In Patients With Hypothalamic Obesity
por: Roth, Christian L, et al.
Publicado: (2023)

Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
por: Haws, Robert, et al.
Publicado: (2020)

SAT-606 Distribution of Beta Klotho Gene Expression in the Mouse Brain
por: Bono, Bianca S, et al.
Publicado: (2020)

SUN-606 Identification of NASH Using Data from NHANES III
por: Friedman, Theodore C, et al.
Publicado: (2020)

MON-LB019 Setmelanotide (RM-493) Reduces Food Intake and Rapidly Induces Weight Loss in a Mouse Model of Alström Syndrome
por: Stephenson, Erin, et al.
Publicado: (2019)

The efficacy and safety of setmelanotide in individuals with Bardet-Biedl syndrome or Alström syndrome: Phase 3 trial design
por: Haws, Robert M., et al.
Publicado: (2021)

Interview-Based Patient- and Caregiver-Reported Experiences of Hunger and Improved Quality of Life with Setmelanotide Treatment in Bardet-Biedl Syndrome
por: Ervin, Claire, et al.
Publicado: (2023)

MON-606 Changes in Eating Frequency but Not in Food Quality During Time Restricted Eating: Analysis from the See Food Study
por: Malaeb, Samar, et al.
Publicado: (2020)

ODP003 Different Phenotypes of Obesity: Focus on The Intestinal Microbiom and The Adipomyokin Profile
por: Volkova, Natalya, et al.
Publicado: (2022)

ODP010 Relaxin Receptor RXFP1 Knockout in Adipose Tissue Progenitor Cells Results in Resistance to High Fat Diet-Induced Weigh Gain
por: Bennett, Robert, et al.
Publicado: (2022)

ODP002 ASSOCIATION BETWEEN OBESITY AND DIABETES POTENTIATES RENAL FUNCTION IMPAIRMENT IN BARIATRIC PATIENTS
por: Naliato, Erika
Publicado: (2022)

ODP009 Obesity-related Conditions in Adults with Overweight and Obesity in the United States: A Cluster Analysis
por: Chiu, Kevin, et al.
Publicado: (2022)

ODP008 Nonalcoholic Fatty Liver Disease (NAFLD) Impacts Weight Loss after Bariatric Surgery
por: Abu-Rumaileh, Mohammed, et al.
Publicado: (2022)

ODP591 Obesity and Weight Loss Apps in COVID-19 Era: Do They Help Both the Doctor and the Patient?
por: Lawrence, Rebecca, et al.
Publicado: (2022)

ODP005 Molecular Characterization of Early Adipose Tissue Remodeling and Fibrosis in a Murine Model of Diet-Induced Obesity.
por: Timms, Katie, et al.
Publicado: (2022)

ODP001 AKR1C2 Activity in Abdominal Adipose Tissue of Women with or without Excess Visceral Adiposity
por: Ostinelli, Giada, et al.
Publicado: (2022)

ODP014 Safety and Efficacy of IBI362 (LY3305677) 9 mg and 10 mg in Chinese Adults with Overweight or Obesity
por: Ji, Linong, et al.
Publicado: (2022)

ODP006 Multidisciplinary Weight Management Improves Body Weight And Body Mass Composition In Breast Cancer Women Undergoing Adjuvant Chemotherapy
por: Nguyen, Vivien, et al.
Publicado: (2022)

SUN-LB016 The Long Term Effects of Resveratrol Supplementation during Pregnancy and Lactation on Adipose Tissue Morphology in the Adult Offspring
por: Ros-Pérez, Purificación, et al.
Publicado: (2019)

ODP007 Nephron Specific ATP6AP2 Knockout Increases Urinary Excretion of Fatty Acids while Decreasing Renal Cortical Megalin Expression
por: Culver, Silas, et al.
Publicado: (2022)

ODP011 Single Nuclei RNA-Sequencing of Frozen Human Adipose Tissue and PET/CT Imaging Coupled With Deep-Learning Reveals Single-Cell Landscape and Transcriptional Dynamics Related to Adipocyte Hypertrophy and in Vivo Dysmetabolism
por: Ye, Run Zhou, et al.
Publicado: (2022)

ODP004 Glucose Profiles and Insulin Sensitivity in Adults with Overweight/Obesity Participating in a Weight Loss Intervention based on Early Time-Restricted Eating plus Daily Caloric Restriction vs Daily Caloric Restriction Alone
por: Jeffers, Rebecca, et al.
Publicado: (2022)

SAT-593 Sex-Specific Modifications in MicroRNAs Contained in Exosomes of Astrocytes in Response to Palmitic Acid
por: Chowen, Julie Ann, et al.
Publicado: (2020)

FRI076 Colchicine Treatment Effects On The Gut Microbiome In Adults With Metabolic Syndrome, Insulin Resistance, And High C-reactive Protein (CRP): A Secondary Analysis Of A Randomized, Placebo-controlled Clinical Trial
por: Kisimba, Celine M, et al.
Publicado: (2023)

LBODP003 Effects Of 4-weeks’ Treatment With Intraperitoneal Colchicine On Metabolic And Inflammatory Outcomes In Mice Fed A High-fat Diet
por: Arner, Brooke E, et al.
Publicado: (2022)

Fatty Acids Modify the MicroRNA Content of Exosomes Released by Hypothalamic Astrocytes and the Response of POMC Neurons to These Exosomes
por: Collado-Pérez, Roberto, et al.
Publicado: (2021)

LBODP109 Astrocytes Affect The Metabolism Of Proopiomelanocortin (pomc) Neurons Through The Release Of Exosomes That Are Modified In A Fatty Acid Specific Manner
por: Collado-Pérez, Roberto, et al.
Publicado: (2022)

LBODP002 Phase II Open-label Pilot Trial Of Liraglutide In Adolescents With Obesity After Vertical Sleeve Gastrectomy: Interim Results From 8-weeks Of Treatment
por: Fatima, Syeda Z, et al.
Publicado: (2022)

Effects of Colchicine on Measures of Lipolysis in Adults With Obesity
por: Sarrafan-Chaharsoughi, Zahra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9493m3b4bm1a6huig6pnj7au60